Market News & Trends
Absorption Systems' Innovation Rewarded With New US Patent for CellPort Technologies
Absorption Systems recently announced a new US patent issued on January 31 that protects intellectual property around its P-glycoprotein (P-gp) knockdown cell line within the…
Aptar Unveils Innovative Delivery Devices for the Future
Aptar Pharma, a world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, recently announced it had presented its latest innovation,…
Avanir & Concert Announce Exclusive License Agreement
Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into an exclusive license agreement that provides Avanir worldwide rights to develop and…
Haselmeier Establishes New Pen Injector Assembly Facility
Haselmeier, a leading designer and manufacturer of pen injection systems, recently announced it will establish a new manufacturing facility in Bangalore, India, to produce and…
Neuronex Announces $100-Million Merger Agreement
Neuronex recently announced the signing of a merger agreement with Acorda Therapeutics that, if completed, would result in full acquisition by Acorda and potential payments…
2/21/2012
Catalent Pharma Solutions & NewMarket Sign Development Agreement Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly…
Catalent Pharma Solutions & NewMarket Sign Development Agreement
Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly formulate and develop a portfolio of products for…
Curis & Debiopharm Announce Initiation of Phase Ib Expansion Study
Curis, Inc. and Debiopharm Group recently announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90)…
DARA BioSciences Signs Exclusive Agreement With Uman Pharma
DARA BioSciences, Inc. recently announced it entered into an exclusive US agreement with Uman Pharma Inc. for commercial rights to gemcitabine, DARA's second newly licensed…
IntelGenx Announces License Agreement With Edgemont Pharmaceuticals
IntelGenx Corp. recently announced it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC for the commercialization of IntelGenx's lead product CPI-300 in US.…
Malvern & Postnova to Deliver Solution for Characterizing Challenging Particulate Systems
Malvern Instruments and Postnova Analytics recently announced they are co-operating to deliver the combined FFF (Field-Flow Fractionation) and DLS (Dynamic Light Scattering) solutions that today…
Sandoz Buys Rights to Apricus Biosciences' Drug for $28 Million
Apricus Biosciences, Inc. recently announced its wholly owned subsidiary NexMed, Inc. has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to…
Bend Research Signs License Agreement With Eli Lilly & Company
Bend Research Inc., a leading independent drug formulation development and manufacturing company, recently announced it has entered into a licensing agreement with Eli Lilly and…
CHEMO & Particle Sciences Partner to Provide the Only Development-to-Commercialization Solution
Particle Sciences Inc. and CHEMO recently announced they have formed a partnership to offer complete contract product development and commercial manufacturing of hormone-eluting devices. Particle Sciences…
Cytomedix Acquires Aldagen
Cytomedix, Aldagen, acquisition details, 5 million dollar stock purchase, PRP platform technology, Martin Rosendale, cell selection technology Cytomedix, Inc. recently announced the completion of the…
Daiichi Sankyo Seeks to Acquire Three Indian Pharma Firms
Daiichi Sankyo, which in 2008 acquired Ranbaxy, is in takeover talks with at least three mid-sized Indian pharmaceutical companies. Daiichi Sankyo has appointed IMS Consulting…
Vectron Biosolutions Obtains Strong Results for Biosimilar Production
Vectron Biosolutions recently announced they have obtained strong results for manufacture of selected biosimilar proteins using its proprietary E. coli expression technology. The study was…
Watson Seeks Brand-Drug Profits in Shift From Copycats
Watson Pharmaceuticals Inc. CEO Paul Bisaro is looking to acquire brand-name drug assets and make a future ""˜transformational" purchase as he reshapes the generic-drug maker.…
2/14/2012
Bend Research Signs License Agreement With Eli Lilly & Company Bend Research Inc., a leading independent drug formulation development and manufacturing company, recently announced it…
2/7/2012
Foster Analytical Services Speed Time to Market for Drug Delivery Formulations Foster Delivery Science, a business unit for Foster Corporation, recently announced it has added…
